After Brookline Capital Markets and BMO Capital gave 9 Meters Biopharma (NASDAQ: NMTR) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Naz Rahman maintained a Buy rating on 9 Meters Biopharma yesterday and set a price target of $1.00. The company's shares closed last Wednesday at $0.29, close to its 52-week low of $0.22. According to TipRanks.com, Rahman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -42.2% and a 14.6% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Processa Pharmaceuticals, and Galmed Pharmaceuticals.
https://www.tipranks.com/news/blurbs/9-meters-biopharma-nmtr-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more 9 Meters Biopharma Charts.
9 Meters Biopharma (NASDAQ:NMTR)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more 9 Meters Biopharma Charts.